Drugs / Tenofovir/Emtricitabine
Tenofovir/Emtricitabine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00549198 Comparator | Jun 2007 → Dec 2009 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tenofovir/Emtricitabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00549198 ↗ |
| Known as | tenofovir disoproxil fumarate/emtricitabine | “Recently, the fixed-dose combinations (FDC) KIVEXA™ (abacavir/lamivudine) and TRUVADA (tenofovir disoproxil fumarate/emtricitabine) have facilitated the usage of once-daily regimens.” NCT00549198 ↗ |
| Known as | TRUVADA | “Recently, the fixed-dose combinations (FDC) KIVEXA™ (abacavir/lamivudine) and TRUVADA (tenofovir disoproxil fumarate/emtricitabine) have facilitated the usage of once-daily regimens.” NCT00549198 ↗ |